Incyte delivered a strong finish to 2025, with full-year revenue growing 21% to $5.14 billion and net sales increasing 20% to $4.35 billion, driven by a 53% surge in core business sales ex-Jakafi. Jakafi sales rose 11% to $3.09 billion, while newer products like Opsilura (+33%) and Hematology/Oncology (+83%) provided significant momentum, validating the company's diversification strategy. Looking ahead, management guided for 2026 revenue of $4.77 billion to $4.94 billion (10-13% growth), underpinned by the launch of Jakafi XR, continued double-digit growth in dermatology, and the potential approval of Povircitinib for HS. The company emphasized a 'catalyst-rich' 2026 with 14 pivotal trials underway, positioning Incyte for a sustained growth trajectory driven by its maturing pipeline in MPNs, pancreatic cancer, and colorectal cancer.
| Metric | Value | Change |
|---|---|---|
| Total Revenue (FY25) | $5.14 billion | +21% YoY |
| Net Sales (FY25) | $4.35 billion | +20% YoY |
| Jakafi Sales (FY25) | $3.093 billion | +11% YoY |
| Opsilura Sales (FY25) | $678 million | +33% YoY |
| Hem/Onc Sales (FY25) | $583 million | +83% YoY |
| Core ex-Jakafi Sales (FY25) | $1.26 billion | +53% YoY |
| 2026 Revenue Guidance | $4.77 - $4.94 billion | +10-13% YoY |
Incyte is actively managing the Jakafi patent cliff (2028) through the strategic launch of Jakafi XR in 2026. Management views the XR formulation as a critical tool to drive adherence gains of 15-25% and secure formulary access, targeting a conversion rate of 10-30%. This lifecycle management strategy aims to maintain revenue growth and fund the pipeline, with the potential for nearly $1 billion in XR revenue by 2029.
The company is successfully transitioning from a single-product reliance to a diversified platform, evidenced by core business sales ex-Jakafi growing 53% to $1.26 billion. Management projects this segment will grow another 30% in 2026 and reach $3-4 billion by 2030, driven by the expansion of Opsilura in atopic dermatitis and vitiligo, the uptake of Monjuvi in DLBCL, and the potential launch of Povircitinib for HS.
Incyte's pipeline has reached a new level of maturity with 14 pivotal trials expected to be underway by the end of 2026. Key catalysts include the initiation of Phase 3 trials for the CALR antibody (9-89) in mid-2026, the KRAS G12D inhibitor (734) in Q1 2026, and the TGF beta/PD-1 bispecific (a9o) in colorectal cancer. Management views these assets as 'outlier opportunities' with the potential to drive revenue into the next decade.
The positive Phase 3 data for Monjuvi (tafasitamab) in first-line DLBCL represents a significant commercial opportunity, potentially expanding the drug's addressable market to 30,000 patients annually. Management emphasized that Monjuvi is an 'intensification strategy' added to R-CHOP rather than a replacement, allowing for incremental revenue capture in a setting where 50% of patients still receive standard chemotherapy.
Management is prioritizing the expansion of the JAK franchise into new indications, specifically Hidradenitis Suppurativa (HS) with Povircitinib. With the NDA submitted and acceptance anticipated in Q1 2026, Incyte aims to capture the pre-biologic population where no FDA-approved oral treatments exist. This strategy leverages the company's expertise in JAK inhibition to address high unmet medical needs in immunology.
Incyte faced a significant regulatory setback with Opsilura in Prurigo Nodularis (PN), where the FDA requested an additional Phase 3 trial after one study missed its primary endpoint. Management has paused development in this indication, delaying potential revenue and raising questions about the drug's efficacy profile in certain dermatological conditions despite positive results in other areas.
The looming loss of exclusivity for Jakafi in 2028 remains a primary overhang for the stock. While management is confident in the Jakafi XR launch and the pipeline's potential, the company must execute flawlessly on multiple late-stage trials and launches to offset the projected revenue decline from its flagship product, which currently funds a significant portion of operations.
Management acknowledged taking 'price actions' to expand formulary coverage for Opsilura, which impacted ASP in 2025. While they expect this investment to roll off in 2027, the need to discount to gain access highlights the competitive dynamics within the dermatology market and could pressure margins if sustained or repeated with new products.
The company's aggressive R&D spending, which increased 31% in Q4 and is expected to rise another 10% in 2026, introduces financial risk if pipeline assets fail to deliver. Management is betting heavily on the success of high-risk, high-reward programs like the KRAS G12D inhibitor and CALR antibody, leaving little room for clinical setbacks.
Overall: Management exhibited a high degree of confidence and enthusiasm, frequently characterizing 2025 as a year of 'outlier opportunities' and 'exceptional' performance. They were direct and detailed regarding financial guidance and pipeline timelines, projecting a sense of assuredness in the company's ability to execute on its 'inflection point' strategy in 2026.
Confidence: HIGH - Executives provided specific revenue guidance, detailed trial initiation dates, and clear strategic priorities without equivocation. The language used was assertive regarding the potential of their pipeline assets to replace Jakafi revenue, with phrases like 'fully convinced' and 'transformative' used to describe clinical prospects.
$4.77 billion to $4.94 billion
$3.22 billion to $3.27 billion
$750 million to $790 million
$800 million to $880 million
$1.57 billion to $1.69 billion
$3.495 billion to $3.675 billion
Hedging & Uncertainty: Management generally used direct and assertive language regarding past performance and near-term guidance, but employed more conditional phrasing when discussing late-stage pipeline outcomes and regulatory timelines. Phrases like 'potential to be,' 'if approved,' and 'we expect' were common when discussing future catalysts. However, confidence was high when discussing the science, with Pablo stating, 'We are fully convinced that if you hit this driver mutation... we will get the same type of outcomes.' The hedging was primarily around regulatory interactions ('We look forward to interacting with the agency') and specific trial designs ('I'm going to try not to get too far ahead of ourselves').
Everything we accomplished this past year... has created the foundation for an inflection point in '26 and beyond. - William Meury
Our core business excluding Jakafi has the potential to be as large as Jakafi is today by 2030. - William Meury
We are fully convinced that if you hit this driver mutation... we will get the same type of outcomes. - Pablo Cagnoni
We have a catalyst-rich year ahead... underscoring the breadth, depth, and maturity of our pipeline. - Pablo Cagnoni
We just launched a pediatric indication... The market is really moving... prescribing migrates from steroidal topicals to nonsteroidal topicals. - William Meury
Analyst Sentiment: Analysts were generally inquisitive and focused on execution, asking detailed questions about trial designs, competitive positioning, and specific pipeline mechanics. There was skepticism regarding the PN setback and the pricing dynamics of Opsilura, but overall interest remained high regarding the potential of the CALR and KRAS programs.
Management Responses: Management was responsive and detailed, often deferring specific scientific questions to the relevant experts (Pablo or Steven). They maintained a consistent narrative of growth and pipeline maturity, addressing the PN setback directly but framing it as a unique situation without read-through to other indications.
Detailed discussion on the design and dosing strategy for the CALR (9-89) Phase 3 trial, with management emphasizing the need to address differential potency across mutations.
Clarification on Opsilura pricing, with management explaining that price actions were taken to secure long-term formulary access rather than due to competitive pressure.
Analysis of the Monjuvi (tafasitamab) data in first-line DLBCL, with management highlighting the 'intensification strategy' versus competitors' 'replacement strategy'.
Updates on the KRAS G12D inhibitor (734) program, including the planned Phase 3 trial design and the potential for combination therapies in pancreatic cancer.
Discussion on the regulatory path for Povircitinib in HS, including the potential to capture both biologic-naive and biologic-experienced patients.
Incyte is successfully executing a strategic pivot from a single-product (Jakafi) reliance to a diversified growth platform. The 53% surge in core ex-Jakafi sales demonstrates the commercial viability of new assets like Opsilura and Monjuvi. The 2026 guidance implies sustained double-digit growth, underpinned by a maturing late-stage pipeline with 14 pivotal trials. While the PN setback for Opsilura is a minor hiccup, the potential approval of Povircitinib in HS and the launch of Jakafi XR provide near-term catalysts. Long-term value creation hinges on the 'outlier' potential of the CALR and KRAS programs, which management is highly confident in. The risk/reward profile remains attractive given the visible path to $3-4B in core revenue by 2030.
Management noted a sustained shift in prescribing patterns from steroidal to non-steroidal options in dermatology, driven by long-term safety concerns. This trend favors Incyte's JAK inhibitor franchise and supports the growth outlook for Opsilura and Povircitinib.
The FDA's request for an additional trial in Prurigo Nodularis highlights a stringent regulatory bar for dermatological indications, potentially delaying revenue and increasing development costs. However, interactions on other programs (HS, Oncology) appear constructive.